THE 2001 TOP 150 HEALTHCARE RANKINGS: Globalization is pushinghealthcare PR to new levels of growth. Julia Hood reports

Until this year, the healthcare PR sector has lived in the shadow

of its sexy hi-tech sibling, which is odd for a market that grew nearly

30% last year. As a result, those slightly inappropriate adjectives that

have been attached to healthcare PR over the years - steady,

conservative, resilient - have suddenly made it all the more


"It's an old axiom that when the economy gets bad, people get sick and

healthcare gets good," says Dorothy Pirovano, principal with Public

Communications International (PCI).

Indeed, the healthcare PR market is now worth dollars 434 million in the

US alone, with the majority of the work (76%) coming from

pharmaceuticals, diagnostics and clinical care. The HMO/services sector

makes up approximately 15%. The remainder comes from government


The biggest healthcare PR practice is Ketchum, which ousted Porter

Novelli from the top spot following a 23% increase in revenues. Among

the top 10 healthcare agencies, only Hill & Knowlton posted a revenue

decrease, while the sector's best performer was GCI Group/APCO

Associates, which reported 61.4% growth (see profiles, p.27).

Emerging markets

Those working in healthcare PR retain an optimistic attitude toward the

future of the sector. First among the opportunities is worldwide

expansion - global capabilities are key to attracting new business.

"For the first time ever, all of our top 10 clients are multinational

accounts," notes David Catlett, director of Ketchum's global healthcare

practice. "Most new clients want multinational or global support."

Catlett adds that incrementally introducing existing US clients to

international markets has been crucial to the agency's success, and this

is especially true for pharmaceuticals.

"Pharmaceutical companies are truly becoming more globally focused

because the markets they have been in are mature or are tapped," says

Ann Moravick, managing director of Manning, Selvage & Lee's global

health practice.

"They need to look to emerging markets."

Traditionally, pharmaceutical firms have let their brands speak for

them, but as they become more aware of the importance of building a

corporate image, global views follow.

"Our clients are recognizing and focusing on global branding, both

corporate and product," says Nancy Turett, Edelman's global director of


"We are working with clients like Pfizer and Johnson & Johnson on

bringing together the best of global with the best of local."

Of course, with new markets come new concerns, including

country-specific regulations. "Companies want us to work with them on

strategy and understanding the nuances of different countries," says

Kathy Cripps, Hill & Knowlton's executive managing director and

co-director of the national healthcare practice.

MS&L, for example, is working on a global campaign to enhance access to

certain treatments, helping advocacy groups in local communities around

the world lobby for reimbursement.

"You can do a lot of direct-to-consumer work in this market," says

Moravick, "but we have to tweak the concept for its applications in

Europe, Latin America and Asia depending on the nuances of regulation

from market to market."

For GCI, international clinical trial recruitment has been a major


The agency is currently working with Janssen-Cilag on centralizing its

strategies for all its regions. GCI also works on an international

account with Pfizer Animal Health.

In addition, Chandler Chicco Agency was recently given its first global

brief for Amgen. "The company is the biggest biotech firm in the world,

but it is starting from scratch in using one of the biggest drugs they

have for global marketing communications," says agency co-founder

Gianfranco Chicco.

The pricing issue

One of the side effects of globalization is a heightened focus on drug

prices, particularly in countries where the average person's annual

income would not pay for even two months of medication.

This issue came to a head in April when 39 drug manufacturers dropped a

lawsuit against the government of South Africa for buying branded AIDS

drugs at lower prices in other countries. Although the suit was

instigated under the guise of patent protection, few felt sympathy for

the drug companies.

"It did cause damage," says Michael Durand, director of PN's global

healthcare practice. "I was looking at European newspapers, and the

headlines were absolutely brutal toward the drug industry."

Pricing tussles resonate in the US as well, as the government works on a

new Medicare prescription drug benefit. In addition, the AFL-CIO

recently demonstrated in front of Pfizer headquarters over the cost of

drugs for senior citizens, earning headlines for dressing up protesters

like pill bottles.

A more subtle indication of this trend comes from the fact that the

over-the-counter status for allergy medications Claritin, Allegra and

Zyrtec is not being sought by the manufacturers, but by a managed-care

company concerned with keeping costs down.

On the flip side, Novartis' announcement in May of FDA approval for its

leukemia drug Glivec demonstrated how pharmaceutical companies are

beginning to preempt price worries. Prior to Glivec's approval, Novartis

- with the help of Ruder Finn - reached out to patient groups to inform

them of an innovative strategy that involves tailoring the price of a

drug according to the patient's income. Novartis' CEO came to the US

from the company's headquarters in Switzerland to announce the plan, an

event that was widely covered by the press.

"The way you handle something that is life saving is very important,"

says Kathy Bloomgarden, president of Ruder Finn. "The company was very

bold and brought together a formula."

Creating new pricing structures is just one way companies can address

the PR challenge. "If a drug has to be a certain price, there are other

benefits that make this more valuable to the patient or patient's

family, such as resources that can help them get better faster," says

Laura Schoen, president of BSMG global healthcare.

Drugs that are likely to be targeted for pricing scrutiny should be

identified early. Moravick endorses communicating three key issues:

pricing rationale, the degree to which research and development are

necessary and the benefits the company or the drug provides to the

physician and patient communities.

"It is a complicated communications challenge because there is a degree

to which companies will always be perceived as the bad guy," Moravick

says. For this reason, some companies are still reluctant to enter the

debate. "The industry is sometimes not inclined to speak because it

feels saying nothing is better than fighting an uphill battle."

Searching for the next Viagra

The production of blockbuster drugs seems to be a trend these days, and

it's become a big priority for pharmaceuticals. Among the most

recognizable drugs on the market are Pfizer's Viagra, currently promoted

by PN; Claritin (Schering-Plough), handled by Edelman; Aventis' Allegra,

managed by Cohn & Wolfe; and Pharmacia's Celebrex, handled by MS&L.

But there's a risk to promoting a blockbuster. Catlett says the stock

price of individual companies is far more susceptible to the performance

of individual drugs than ever before. "A major pharmaceutical recently

had news that a large brand was going off patent earlier than expected,

and the stock of the company went down 30% in one day," he says.

Regardless, every company wants to uncover the next headline-making

medication, and every agency wants to help create the buzz that makes it

all happen.

"The number of blockbuster drugs is really affecting the company's

ability to grow and profit," affirms Bloomgarden. "And the success in

creating a blockbuster really depends on the early days of the


Indeed, PR is a crucial tool in the blockbuster boom, but timing is


"You need to be sure you are out there early, manifesting understanding

of the science within regulatory guidelines," says Ilyssa Levins,

chairman of GCI's healthcare practice. "The survival window is from

launch to six months after. If you have not gotten everyone waiting to

ask for your drug after launch, then that survival window closes very


Because of this, companies will spend most of their marketing dollars on

the pre-launch and first six months of a drug. Agencies may be brought

in as early as 12 months before approval by the FDA, but more often they

are recruited six months prior.

In the future, genomics will most likely alter the definition of a

blockbuster drug, because the products will be more targeted toward

individuals rather than entire therapeutic categories. "The questions

will be, 'What will define a blockbuster, and how does it correspond to

the move toward more targeted genomics?'" says Ame Wadler, chairman of

Burson-Marsteller's healthcare practice. "We're going to have to get

closer to prescribers and patients as we get more targeted."

Convincing the consumer

Direct-to-consumer (DTC) advertising and marketing matured even further

in 2000, up to dollars 2.6 billion from dollars 1.8 billion in 1999. In

addition, spending has already grown 13% since this time last year.

While DTC advertising was never actually prohibited by the FDA, it was

not until 1997 that companies were allowed to broadcast commercials

without listing every possible side effect attached to the drug. Since

then, the number of pharmaceutical ads on television and in print

publications has skyrocketed. (The Internet and other promotional media

also fall under the DTC category.)

Questions have been raised in Senate and FDA hearings, as well as in the

media, about the wisdom of arming consumers with drug information.

There is a perception that consumers are walking into doctors offices

and demanding drugs based on promotions alone, and that doctors may be

too compliant about obliging them with prescriptions.

From a PR standpoint, the concern is that physicians and consumers may

not have the same level of awareness about new therapies and are

therefore unable to communicate with each other effectively.

"The danger is that while the consumer is more empowered and has more

say, you can never lose sight of the fact that it is still the physician

or clinician who is the gatekeeper," says Roger Fischer, CEO of Fischer

& Partners. "If that physician has not heard about it through

traditional channels - peer-review literature, medical meetings - the

dollars are truly wasted in DTC. Patients still want the physician to

acknowledge and endorse the therapies."

Drug companies also need to pay attention to the debate because the push

for over-the-counter status for allergy drugs may be related to people's

attitudes about their safety, which are often gained from glossy DTC


"The pharmaceutical industry has been put on notice that if we do too

good a job convincing people that drugs are harmless and just like

candy, we can't blame them for thinking they are harmless," explains Kym

White, Ogilvy's co-managing director of its healthcare practice.

On the horizon

The Senate's new Democratic shift has brought issues such as the

patient's bill of rights and Medicare reform back to the forefront. "The

entire industry is waiting to see what happens in Washington," says Ame

Wadler, Burson's healthcare practice chair.

In the past year, many government healthcare departments - including the

Centers for Disease Control and the Healthcare Financing Administration

- have changed the way they retain agencies, gathering a group of

preferred vendors to compete against one another for individual


Managed-care organizations are focusing on corporate image in an effort

to redress the balance of the industry's coverage, which is devoted

almost exclusively to denial of coverage. "No industry has been more

taken to task and lambasted than the HMOs," says Fischer. "I think it is

changing slowly. They are getting better at communicating their value in

the healthcare system."

Healthcare litigation is another emerging PR opportunity. "PR is perfect

for shaping the story and the ultimate debate," says Katherine Metcalf,

EVP and MD of healthcare for Cohn & Wolfe. That agency is retained by

Glaxo SmithKline for its Paxil account, a product that just weeks ago

was hit with a dollars 8 million judgment in court when it was alleged

the drug caused a man to kill his wife and then himself. "Many companies

leave their lawyers to handle all of this, saying we'll focus on winning

in the courtroom," Metcalf says. "But there is something called the

court of public opinion."

New business prospects also exist in genomics and proteomics. As the

baby-boomer population ages, government will have a greater focus on

issues of aging and dying, according to Marilyn Castaldi, director of

Fleishman-Hillard's healthcare practice. According to H&K's Cripps, the

issues of weight management also holds potential for future growth.

PR predictions

With so much to shoot for these days, some healthcare practice leaders

believe the sector will outperform the PR market as a whole (predicted

to grow 11%, according to a March survey by the Council of PR Firms).

Metcalf at C&W predicts "similar growth to the 30% last year, or even

slightly more." However, Ketchum's Catlett is a tad more cautious. "I

think 30% is a bit optimistic," he says.

Although healthcare is not as susceptible to market machinations as

other sectors, there's still a sense of fiscal caution. "I see a growing

conservatism on the part of clients in terms of the amount of money

being invested in PR and how quickly they make decisions about how to

invest," says Tom Beall, co-managing director of Ogilvy's healthcare


As companies are so focused on the bottom line, PR agencies are expected

to quantify their contributions more than ever before. "Now that PR has

largely grown up, it is being held to the same standards as to whether

you are truly having an impact on the sales of the drug," says PN's


"Can it be measured? Many companies are asking that, and if they aren't,

they shortly will be."

Durand and others say they are still waiting for clients to consistently

consider PR on par with advertising and other marketing initiatives. It

is tough to prove how much an agency is capable of if prospective

clients still believe PR is boilerplate. "I got an RFP a couple of weeks

ago that said this is a product for a certain condition, but we can't

tell you about it," Durand says ruefully. "You just sort of throw up

your hands."

G: 1 KETCHUM - dollars 42,092,000

Ketchum regained its No. 1 position from Porter Novelli in 2000 with a

23% growth spurt. David Catlett, director of the dollars 42 million

global healthcare practice, attributes much of last year's good news to

the expansion of existing accounts. For the first time, all of Ketchum's

top 10 clients are multinational accounts, and the firm has dedicated

healthcare teams in all of the G5 countries. "Most new clients want

multinational and global support," he explains. "We expanded with

clients into the international arena." Wyeth Ayerst is one example;

another is Roche, which gave the agency a new brief to work on its

international HIV franchise. The Washington, DC office picked up new

business from Eli Lilly. Elan pharmaceuticals has also increased its

business. The San Francisco office picked up business with the biotech

Medtronic, which is working on a bone morphogenic protein.

Ketchum also won additional business from Genentech and helped

HealthSouth announce plans for the world's first digital hospital.

Some of these accounts were won at very short notice, notes Catlett. "We

won one account over the telephone. Maybe it is because Ketchum is

established as a healthcare agency."

New hires include Laurie Flatt, formerly of Cohn & Wolfe and the Centers

for Disease Control, as VP in the Atlanta office; Jill Mortensen as

associate director of healthcare in London; David Gallagher as head of

the European practice; Erinn White as VP heading up the Roche account;

and Jim Stanley as SVP in Washington, DC.

E: 3 EDELMAN - dollars 38,883,571

Nancy Turett calls 2000 "a year of convergence and globalization." She

could also add "a darn good one." With 59% growth, Edelman's revenues

grew from dollars 24 million to dollars 38.8 million, and the practice

now employs about 250 people worldwide. Client priorities have shifted

to global branding on both product and corporate levels, and, says

Turett, Edelman has responded.

"They are struggling the same way agencies are on how to respect the

globalization of the media, the marketplace and consumer attitudes," she

explains. The challenge is to form an international strategy without

undermining the crucial role of local practices. Clients like Johnson &

Johnson (J&J) and Pfizer have brought Edelman in to help devise

practices on global brand development combined with local marketing.

Turett adds that greater convergence of different practices has also

taken place, with Edelman using its size and diversity to offer

integrated services. An example is bringing together bioscience and

consumer capabilities.

New 2000 hires include Mark Chataway, European healthcare practice

chair; Antje Burbach, MD, Edelman health Germany; Carolyn Paul,

international business development director; and Howard Tag, director of

reimbursement in Washington, DC. Edelman gained new business through a

global strategy account with Merck and expanded international briefs

with Pharmacia's Zybox and Rogaine/Regaine. New accounts also included

Procit and Grifulvan-V for J&J. The firm's work on J&J's Ortho EVRA

patch has also expanded.

Edelman is also working with Gilead Sciences on Tenofovir, a pre-launch

HIV drug. "Our work is about helping people who deal with a medical

condition and integrating it into the their lives," she says.

G: 9 GCI GROUP/APCO WORLDWIDE - dollars 21,459,204

Revenues for GCI/APCO, the fastest growing top 10 healthcare agency,

bounced 61% in 2000 to dollars 21.4 million, reflecting an increased

focus on working with clients early in the drug development process. "We

offer services that start early in phase II or phase III clinical trials

and continue through launch," says Ilyssa Levins, chairman of GCI


Levins also points to GCI's global clinical trial recruitment (CT)

service as one of its most important offerings. "We developed our CT

practice 10 years ago," Levins says. "We are executing clinical trials

for Janssen-Cilag with a headquarters of centralized strategies for them

in all regions of the world customizing that strategy." GCI helped

develop the launch strategies for two blockbusters released in 2001,

Astra Zeneca's Nexium and Novartis' Starlix. Other new clients include

Pfizer Animal Health's Revolution brand, Boehringer Ingelhelim's

Viramune brand and Aventis' Taxotere. With 200 employees around the

world, GCI hired Alan Archer in 2000, who joined the team from Glaxo

SmithKline to head up GCI's European practice.

APCO Worldwide has focused primarily on public affairs. "We have been

involved with pharmaceutical coalitions around federal issues," says MD

and SVP Neal Cohen. APCO works with the Better Hearing Institute,

Citizens for Better Medicine, a range of managed care companies and a

coalition concerned with vaccines. APCO also works on product launches,

but it takes a very different approach than GCI. "We look at audiences

that can be strategically engaged around the launch," Cohen explains.

"We are also involved in the FDA process."

G: 20 PUBLIC COMMUNICATIONS - dollars 3,657,287

Posting fee income of dollars 2.6 million in 2000, Public

Communications' (PCI) healthcare performance leapt by 134% over the

previous year. Although it's a generalist agency, the firm works in all

the major healthcare areas including hospitals, medical associations,

pharmaceutical companies, medical device manufacturers, consultants and

insurers. The agency has had healthcare clients since its inception in

1963, and more than half its 55 employees specialize in healthcare. One

successful strategy is cross-pollinating different accounts. "We have

worked with the American Academy of Dermatology for 15 years, and they

came up with an idea to do skin cancer screening with major league

baseball teams," says Dorothy Pirovano, principal and chairman.

Fortunately, the firm also works with the Chicago White Sox and had an

intimate understanding of the complexities of staging an event with

baseball players. "We were able to take the burden off the team, and off

the client, so we could operate this with little effect on either side."

PCI has expanded relationships with long-term clients, managing

screening programs with the American College of Allergy, Asthma and

Immunology, and for the Society of Cardiovascular and Interventional

Radiology. New business in 2000 included the St. Louis Children's

Hospital. The biggest 2000 account win was Glaxo SmithKline, doing media

relations and community outreach with their HIV/AIDS products. "We've

worked in the HIV/AIDS field since 1981," Pirovano says. "I was at the

conference where the scientists first identified AIDS. It was chilling

to be standing in the Glaxo presentation room a year ago talking about

the same syndrome."

G: 33 JAMES A. FYOCK & ASSOC. - dollars 1,656,539

Novant Health is the biggest client Fyock has ever had. It not only

propelled the agency's revenues up 924% to dollars 1.6 million, but also

changed the way the agency thinks. Fyock was approached by Novant, a

newly formed health services network created by the merger between

Presbyterian Healthcare System in Charlotte, NC, and Carolina Medicorp

in Winston Salem, NC in the fall of 1999. Fyock conducted a full-scale

communications audit, entailing interviews with 65 executives, middle

managers and marketing staff in both regions, and a review of every

piece of communications going out of both offices, internal and

external, and found that "PR and marketing purchases were made in

knee-jerk reaction to competition," recalls SVP Rachel Barron.

But the real surprise for Fyock came after the report was submitted,

when the CEO asked the firm to assume all responsibility for the PR and

marketing function for 2000-2001, including developing a marketing plan

and writing job descriptions.

"Our assignment was to help them get on their feet and be

self-sufficient by 2001," says Barron. James Fyock himself served as

acting SVP at Novant until the company found a permanent hire. By the

end of 2000, Fyock finished the work - a year ahead of schedule - and

even had dollars 1.5 million left in the budget to return to Novant.

Barron says with a total staff of 25, "we're not big enough to have a

healthcare practice." Yet, the firm has worked also with Wake Forest

University Baptist Medical Center and the North Carolina Eye Bank.

"Novant had a tremendous impact on us," Barron says. "We are beginning

down the road of finding out where this agency is going." Watch this


G: 36 BARKSDALE BALLARD - dollars 1,402,753

When it was launched in 1989, Barksdale Ballard positioned itself as a

mid-size generalist firm, with clients in banking, telecommunications,

government and postal service. But a profound shift took place in this

agency as a result of its work over the past five years with the Robert

Wood Johnson Foundation's Last Acts, a program that was launched in 1996

after a dollars 28 million study revealed many Americans die alone, in

pain, with their wishes ignored. "This campaign intends to change that,"

says Mike Ballard, president. "We have discovered our true passion and

are now focusing our skills on the challenges and opportunities of

aging." The growth of this account helped push Barksdale Ballard's

revenues up an astonishing 1077% in 2000, from dollars 119,000 to

dollars 1.4 million. Barksdale focuses on constituency relations and

coalition building for the campaign, which has 600 partners ranging from

the powerful AARP to small palliative care groups in local


The agency also coordinated with the program's workplace committee and

put together a set of best practice guidelines, currently under review,

for addressing the needs of employees who are taking care of the


Other clients include a woman who is documenting her fatal illness on a

Web site, and PBS, which retained Barksdale for outreach on a new series

about care giving provisionally called And Thou Shalt Honor. Ballard

says all 12 members of the agency's staff share an abiding interest in

their mission. "I think we have found our passion, and I emphasize

'we,'" Ballard says. "Everyone here is deeply committed to what we are


CHANGE IN RANKING: G: Climber, H: Faller, E: No change

TOP 150

Rank Agency Name HC Income Change

2000 1999 2000 %


1 2 Ketchum 42,092,000 23

2 1 Porter Novelli International 40,853,000 12

3 3 Edelman Public Relations Worldwide 38,883,571 59

4 4 Ogilvy Public Relations Worldwide 35,649,300 38

5 5 Fleishman-Hillard 35,080,000 44

6 6 Ruder Finn 32,100,000 40

7 7 Manning, Selvage & Lee 28,136,737 -

8 9 Burson-Marsteller 23,694,000 12

9 12 GCI Group/APCO Associates 21,459,204 61

10 10 Hill & Knowlton 20,775,000 -26

11 11 BSMG Worldwide 17,904,078 46

12 19 Weber Shandwick Worldwide 13,989,785 15

13 16 Noonan/Russo Communications 12,400,000 43

14 13 Cohn & Wolfe 12,365,000 19

15 14 Chandler Chicco Agency 11,831,302 8

16 21 Fischer & Partners 5,395,134 50

17 24 Dorland Sweeney Jones 4,522,000 31

Health Communications

18 NEW Publicis Dialog 3,969,400 67

19 23 PResence Euro RSCG 3,780,000 8

20 30 Public Communications 3,657,287 135

21 NEW Spectrum Science Public Relations 3,056,980 30

22 22 The MWW Group 2,878,168 -17

23 20 Rowland Communications Worldwide 2,595,000 -31

24 NEW Lippert/Heilshorn & Associates 2,389,722 67

25 34 Devries Public Relations 2,321,202 65

26 NEW Magnet Communications 2,149,000 -

27 36 Belsito & Co. 2,000,340 55

28 29 Equals Three Communications 1,932,000 0

29 48 Duffey Communications 1,871,767 87

30 42 Stanton Crenshaw Communications 1,750,000 59

31 27 Makovsky & Co. 1,727,000 -27

32 NEW Signova 1,681,980 381

33 110 James A. Fyock & Associates 1,656,539 925

34 37 Perry Communications 1,509,850 21

35 49 Hager Sharp 1,448,049 -

36 38 Barksdale Ballard 1,402,753 1077

37 33 Garrett Yu Hussein 1,279,529 -

38 61 Carter Ryley Thomas 1,253,493 -46

39 50 M Booth & Associates 1,106,653 -

40 NEW KPC Public Relations 1,095,994 9

41 53 Seyferth Spaulding Tennyson 1,037,500 18

42 59 Stoorza Communications 1,009,050 46

43 NEW Earle Palmer Brown/PR 1,000,000 -

44 NEW Corporate Technology 976,960 678

45 56 The Rasky/Baerlein Group 961,254 24

46 51 Padilla Spear Beardsley 934,517 4

47 62 Patrice Tanaka & Co. 922,000 54

48 58 Cramer-Krasselt 915,000 31

49 70 Dye, Van Mol & Lawrence 828,383 55

50 117 The Standing Partnership 773,862 461

51 74 McNeely Pigott & Fox Public Relations 723,021 36

52 39 Gerbig, Snell/Weisheimer & Associates 700,000 -

53 NEW Tunheim Group 641,080 1364

54 NEW Edward Howard & Co. 641,000 -

55 54 The Nixon Group 638,526 -26

56 84 Eric Mower & Associates 600,000 48

57 NEW Imagio I JWT Technology 600,000 500

Advertising and PR

58 NEW Regan Communications Group 600,000 20

59 67 Katcher Vaughn & Bailey Communications 595,000 17

60 69 Sawchuck, Brown Associates 545,000 1

61 82 Ackermann Public Relations & Marketing 541,547 50

62 NEW Robin Leedy & Associates 496,122 27

63 NEW DCS Group 495,574 -15

64 71 PRX Strategic Marketing Communications 493,286 8

65 45 PR21 476,976 -57

66 52 PAINE PR 583,192 -34

67 57 Rogers & Associates 450,370 -39

68 NEW Pantin/JGR/Public Relations 442,545 -

69 NEW Hanser & Associates 416,572 61

70 NEW McBride PR 400,000 -

71 NEW DDB Public Relations 400,000 -

72 80 Berry Associates Public Relations 392,618 -4

73 98 Thomas Rankin Associates 383,215 -

74 NEW Bishoff Solomon Communications 381,120 795

75 93 Southard Communications 378,750 58

76 NEW Marcus Thomas Public Relations 373,052 -28

77 NEW Richard French & Associates 348,901 -

78 147 Jacobs & Prosek PR 313,709 484

79 87 Anne Klein & Associates 300,982 -

80 76 JohnstonWells Public Relations 284,113 -61

81 129 Toplin & Associates 264,000 147

82 NEW Pacific Rim Resources 254,169 -

83 NEW TransMedia Group 250,000 -38

84 90 G.S. Schwartz & Co. 250,000 0

85 NEW Adam Friedman Associates 250,000 100

86 NEW Jasculca/Terman & Associates 238,772 149

87 105 Guthrie/Mayes Public Relations 238,000 24

88 114 Agnes Huff Communications Group 237,444 -

89 104 Schenkein 231,700 19

90 NEW Hayslett Sorrel 226,574 -

91 107 Creative Response Concepts 223,548 23

92 NEW OBPR 221,114 -

93 NEW Triad Communication 206,701 56

94 101 Vollmer Public Relations 201,759 -8

95 60 Widmeyer Communications 196,318 -71

96 141 The Vandiver Group 193,147 158

97 75 HLB Communications 192,634 -57

98 73 The Weiser Group 186,000 -22

99 NEW Jack Horner Communications 184,890 -38

100 99 The Headline Group 180,000 -16

101 NEW Sacunas & Saline 177,074 -4

102 NEW Tellem Worldwide 175,500 -5

103 136 Ballard Communications 167,753 70

104 NEW Northlich Public Relations 159,700 4

105 144 Cerrell Associates 159,347 -

106 116 Collins & Co. 153,859 10

107 NEW Fineman Associates PR 151,409 7

108 103 Michael James & Co. 142,869 43

109 44 Middleberg Euro RSCG 138,000 -

110 NEW IMRE Communications 134,400 54

111 NEW The Bivings Group 131,400 -

112 NEW The Gable Group 131,242 987

113 NEW RMR Associates 118,000 -41

114 113 John Bailey & Associates 114,514 -24

115 118 Thorp & Co. 110,784 -49

116 115 MGA Communications 105,384 -27

117 133 BRW LeGrand 100,000 0

118 63 Environics Communications 95,708 49

119 NEW Goff & Howard 95,170 907

120 NEW Pan Communications 92,000 -

121 130 Donnellon Public Relations 91,952 -14

122 140 Pierpont Communications 88,000 -

123 125 Seigenthaler Public Relations 87,382 -36

124 NEW Cushman/Amberg Communications 85,000 -

125 92 The Phelps Group 84,000 0

126 143 Cooper Katz & Co. 80,643 15

127 108 L.C. Williams & Associates 79,978 -55

128 NEW First Experience 74,282 -

129 139 Barkley Evergreen & Partners 72,000 -69

130 102 Caponigro Public Relations 65,375 -67

131 NEW The Beuerman Miller Group 63,380 137

132 NEW Liggett-Stashower Public Relations 62,183 -5

133 NEW Valencia Perez 60,500 267

134 NEW Adler Public Affairs 57,139 -

135 NEW Blades & Associates 50,000 25

136 135 Spelling Communications 48,000 -52

137 NEW BizCom Associates 45,000 -

138 NEW John Mallen Communications 43,101 -

139 134 Gogerty Stark Marriott 34,713 -65

140 NEW Hetrick Communications 33,425 -50

141 NEW Intermark Gillis Public Relations 32,297 194

142 109 Carmichael Lynch Spong 27,000 -

143 NEW Maita-Saviano Public Relations 25,000 -

144 NEW LVM Group 24,710 -

145 NEW The Garrity Group Public Relations 20,000 -80

146 138 Emmanuel Kerr Kilsby 20,000 -43

147 NEW Bayer, Bauserman Co., Advertising & PR 20,000 0

148 NEW Price McNabb 16,309 -

149 NEW Dublin & Associates 14,496 -67

150 NEW Levenson Public Relations 5,103 -

TOTALS 434,869,532 30

SOURCE: PRWeek Agency Rankings 2000 No audit was required for inclusion

in the rankings

DISCLAIMER: While every effort has been made to ensure the accuracy of

these figures, PRWeek cannot accept liability for, nor make financial

guarantees based upon the information in these charts

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in